Current Hepatology Reports

, Volume 13, Issue 2, pp 159–170

Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease

Authors

  • Paola Portillo
    • Division of Endocrinology, Diabetes and MetabolismUniversity of Florida
  • Sahzene Yavuz
    • Division of Endocrinology, Diabetes and MetabolismUniversity of Florida
    • Malcom Randall VAMC
  • Fernando Bril
    • Division of Endocrinology, Diabetes and MetabolismUniversity of Florida
    • Division of Endocrinology, Diabetes and MetabolismUniversity of Florida
    • Malcom Randall VAMC
Fatty Liver Disease (SA Harrison and J George, Section Editors)

DOI: 10.1007/s11901-014-0229-3

Cite this article as:
Portillo, P., Yavuz, S., Bril, F. et al. Curr Hepatology Rep (2014) 13: 159. doi:10.1007/s11901-014-0229-3

Abstract

Nonalcoholic fatty liver disease (NAFLD) is now a frequent cause of consultation for hepatologists and other health care providers. To a significant extent, this is because the metabolic abnormalities associated with obesity and type 2 diabetes mellitus (T2DM) promote liver disease and are more prevalent than ever before. Clinicians must be aware that insulin resistance and hyperglycemia are believed to worsen the natural history of NAFLD, fueling inflammation, hepatocyte injury (ballooning) and fibrosis. End-stage liver disease and hepatocellular carcinoma (HCC) develop more often in this setting. Interventions that reverse insulin resistance and hyperglycemia, may halt or ameliorate the disease process. Therefore, a comprehensive approach is needed for the successful management of these patients that addresses both, the liver-specific and the associated metabolic conditions. This review focuses on the mechanisms by which insulin resistance, and both lipo- and glucotoxicity, are believed to contribute to the development of NAFLD, and on the treatments tested in obese patients with T2DM and NAFLD, as a means to assist practitioners managing these complex patients.

Keywords

Fatty liverNonalcoholic fatty liver disease (NAFLD)SteatosisNonalcoholic steatohepatitis (NASH)TreatmentType 2 diabetes mellitusObesityInsulin resistanceHyperglycemiaLipotoxicityGlucotoxicityPioglitazone, Vitamin EObeticholic acidMetforminExenatideLiraglutide

Copyright information

© Springer Science+Business Media New York 2014